Viva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation

Reuters09-02

<a href="https://laohu8.com/S/01873">Viva Biotech</a> Unveils Breakthrough in Cyclic Peptide <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Paving the Way for Drug Discovery Innovation

Viva Biotech Holdings has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally "undruggable" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: EN63159) on September 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2564870024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 17:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564870024","market":"fut","top_or_hot":-1,"title":"Viva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01873\">Viva Biotech</a> Unveils Breakthrough in Cyclic Peptide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Paving the Way for Drug Discovery Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VBIZF\">Viva Biotech Holdings</a> has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally \"undruggable\" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: EN63159) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 17:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/01873\">Viva Biotech</a> Unveils Breakthrough in Cyclic Peptide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Paving the Way for Drug Discovery Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VBIZF\">Viva Biotech Holdings</a> has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally \"undruggable\" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: EN63159) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1576","symbol_name":"医药外包概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL55j28n:1","article_id":"2564870024","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564870024","pubTimestamp":1756805454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viva Biotech Holdings has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally \"undruggable\" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1576":"医药外包概念","01873":"维亚生物","BK1141":"生命科学工具和服务"},"translate_title":"维亚生物公布环肽疗法突破，为药物发现创新铺平道路","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":0.9},"content_text":"Viva Biotech Unveils Breakthrough in Cyclic Peptide Therapeutics, Paving the Way for Drug Discovery Innovation\n    \n\nViva Biotech Holdings has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally \"undruggable\" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: EN63159) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2564870024","isCrawlerRequest":true}